Autres langues Ligand Pharmaceuticals Incorporated

Actions

LGND

US53220K5048

Marché Fermé - Nasdaq Autres places de cotation 22:30:01 03/05/2024			Varia. 5j.	Varia. 1 janv.
73,9 ^USD	+2,18 %		+4,72 %	+3,47 %

08/04	Ligand Pharmaceuticals Incorporated annonce que de nouvelles données sur le Topiram injectable ont été présentées lors de la 9e conférence du London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures (Colloque Londres-Innsbruck sur l'état de mal épileptique et les crises aiguës)	CI
03/04	Ligand Pharmaceuticals nomme Scott Plesha au poste de directeur général	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Ligand to Report First Quarter 2024 Financial Results on May 7, 2024	23/04
Ligand Pharmaceuticals Incorporated : Certificate of Incorporation/Bylaws - Form 8-K	19/04
Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference	08/04
Ligand Pharmaceuticals Incorporated Announces New Topiram Injection Data Presented At 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference	08/04
Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI	04/04
Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™	03/04
Ligand Pharmaceuticals Appoints Scott Plesha to the Role of Chief Executive Officer	03/04
Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics	03/04
Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference	05/03
Ligand Pharmaceuticals Announces Inducement Grants under Nasdaq Listing Rule 5635(4)	05/03
Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	04/03
Ligand Pharmaceuticals' Q4 Adjusted Earnings Rise, Revenue Falls; Reaffirms 2024 Guidance	27/02
Ligand: Q4 Earnings Snapshot	27/02
Ligand Pharmaceuticals Incorporated Re-Affirms Earnings Guidance for 2024	27/02
Earnings Flash (LGND) LIGAND PHARMACEUTICALS INCORPORATED Reports Q4 Revenue $28.1M, vs. Street Est of $25.7M	27/02
Earnings Flash (LGND) LIGAND PHARMACEUTICALS INCORPORATED Reports Q4 EPS $1.05, vs. Street Est of $0.66	27/02
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results	27/02
Ligand Pharmaceuticals Incorporated Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	27/02
Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®	22/02
Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires	19/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Ligand Pharmaceuticals Incorporated

Actions

LGND

US53220K5048

Autres langues

Filtres